Stock Analysis, Dividends, Split History

PRA / ProAssurance Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price46.55
Volume631,200.00
Market Cap ($M)2,415.54
Enterprise Value ($M)2,682.67
Book Value ($M)1,574.62
Book Value / Share29.37
Price / Book1.53
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 53,457,000
Common Shares Outstanding 53,457,021
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.02
Return on Equity (ROE)0.06
Balance Sheet (mrq) ($M)
Assets4,583.46
Liabilities3,008.85
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues866,149,000.00
Supplementary Insurance Information Premium Revenue738,531,000.00
Net Income107.26
Earnings Per Share Basic2.01
Earnings Per Share Diluted2.00
Cash Flow Statement (mra) ($M)
Cash From Operations149.00
Cash from Investing224.67
Cash from Financing224.67
Identifiers and Descriptors
CUSIP74267C106
Central Index Key (CIK)1127703

Split History

Stock splits are used by ProAssurance Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

ProAssurance Corporation (PRA) CEO Stan Starnes on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Good morning, everyone. Welcome to ProAssurance's conference call to discuss the company's second quarter 2018 results. These results were reported in a news release issued on August 7, 2018, and in the company's quarterly report on Form 10-Q, which was also filed on August 7. (1-0)

ProAssurance (PRA) Q2 Earnings Beat Estimates, Improve Y/Y

2018-08-08 zacks
ProAssurance Corporation’s (PRA - Free Report) second-quarter 2018 operating earnings per share of 48 cents beat the Zacks Consensus Estimate by 26.3%. Moreover, the bottom line improved 20% year over year, mainly driven by growth in its three operating segments along with overall renewal pricing. (3-0)

ProAssurance (PRA) Tops Q2 Earnings and Revenue Estimates

2018-08-08 zacks
ProAssurance (PRA - Free Report) just came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.40 per share a year ago. These figures are adjusted for non-recurring items. (2-0)

5 Solid Reasons to Hold ProAssurance in Your Portfolio

2018-07-12 zacks
ProAssurance Corporation (PRA - Free Report) has been witnessing solid improvement over the past few quarters, majorly driven by acquisitions, accretive to premiums. Shares of this Zacks Rank #3 (Hold) company have gained 5.5% quarter to date, outperforming 2.2% growth recorded by the industry. The company flaunts a value score of B. If you haven’t taken advantage of the share price appreciation yet, it is time for you to retain the stock in your portfolio as it looks promising and is poised to carry the momentum ahead, driven by the following factors. (2-0)

Near-Term Trends Masking The Long-Term Potential For ProAssurance

2018-07-06 seekingalpha
ProAssurance is looking at worsening claims severity in medical liability insurance, but it is better-reserved than most and the market seems to be starting to harden. (6-0)

Silicon Investor Message Boards

This table lists all message boards related to PRA / ProAssurance Corp. on message board site Silicon Investor.

Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit Pray for Edwarda. Pray for Edwarda. Pray for Edwarda.
Praxair - Industrial Gases NYSE:PX Praxair - Industrial Gases NYSE:PX Praxair - Industrial Gases NYSE:PX Prayer Requests Prayer Requests Prayer Requests
PracticeXpert, Inc. :PXPT PREVIOUSLY BOILER ROOM PracticeXpert, Inc. :PXPT PREVIOUSLY BOILER ROOM PracticeXpert, Inc. :PXPT PREVIOUSLY BOILER ROOM Metaphysics and Spiritual Practices Metaphysics and Spiritual Practices Metaphysics and Spiritual Practices
Sepracor-Looks very promising Sepracor-Looks very promising Sepracor-Looks very promising Malathion: What is Rudy Spraying Us With? Malathion: What is Rudy Spraying Us With? Malathion: What is Rudy Spraying Us With?
Hedge Funds Watch, methods and practice, Hedge Funds Watch, methods and practice, Hedge Funds Watch, methods and practice, Option Granting Practices and exploits Option Granting Practices and exploits Option Granting Practices and exploits
CUSIP: 74267C106